Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus OPSYNVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus OPSYNVI.
FILSPARI vs OPSYNVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
OPSYNVI is a dual endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE5) inhibitor. Macitentan blocks endothelin-1 (ET-1) receptors (ETA and ETB), reducing vasoconstriction and proliferation. Tadalafil inhibits PDE5, increasing cGMP levels and causing vasodilation.
200 mg orally once daily, with or without food.
10 mg orally once daily, in combination with tadalafil 20 mg orally once daily.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Terminal elimination half-life approximately 15 hours (range 10–20 hours) in patients with pulmonary arterial hypertension; supports twice-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Primarily fecal (approximately 66% of absorbed dose) and renal (approximately 22% as unchanged drug and metabolites). Biliary excretion is negligible.
Category C
Category C
Endothelin Receptor Antagonist / ARB
Endothelin Receptor Antagonist/Phosphodiesterase-5 Inhibitor Combination (PAH)